Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 2/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 2/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16746500 | 0.87 | HPGD (0.44) | ALPLALPIMAOAMAOBMEN1 | |
| SCHEMBL11871293 | 0.87 | HPGD (0.44) | ALPLALPIMAOAMAOBMEN1 | |
| SCHEMBL11871299 | 0.87 | HPGD (0.44) | ALPLALPIMAOAMAOBMEN1 | |
| SCHEMBL12977432 | 0.82 | ACHE (0.50) | ALPLALPIMAOBGAAPGR | |
| SCHEMBL12977427 | 0.82 | ACHE (0.50) | ALPLALPIMAOBGAAPGR | |
| SCHEMBL12977423 | 0.76 | MAPT (0.53) | ALPLALPIPIM1PIM2MEN1 | |
| SCHEMBL12977425 | 0.76 | MAPT (0.53) | ALPLALPIPIM1PIM2MEN1 | |
| SCHEMBL3370471 | 0.75 | PGR (0.41) | PTPRCMAOAMEN1NPC1KMT2A | |
| SCHEMBL3370477 | 0.75 | PGR (0.41) | PTPRCMAOAMEN1NPC1KMT2A | |
| SCHEMBL15041025 | 0.73 | KMT2A (0.63) | ALPLALPIMAOBMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11050027-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2021-06-29 | — | — | US | disclosed |
| US-20150144924-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2015-05-28 | — | — | US | disclosed |
| US-20150144924-A1 | CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11050027-B2 | Condensed cyclic compound and organic light-emitting device including the same | CCNT1, CRY1, CCNA1 | ERBB2 4457/4885ALPL 3686/4885ALPI 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.